NDAORALTABLET
Approved
May 2004
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
4/8 — Partial
XIFAXAN (rifaximin) by Bausch Health. Approved for hepatic encephalopathy, travelers' diarrhea, clostridium difficile infection. First approved in 2004.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XIFAXAN (rifaximin) is a non-systemic oral rifamycin antibiotic approved for three gastrointestinal indications: hepatic encephalopathy, travelers' diarrhea, and Clostridioides difficile infection. The drug acts locally in the GI tract with minimal systemic absorption, making it suitable for conditions requiring localized antimicrobial activity.
Peak
dominant in travelers' diarrhea and hepatic encephalopathy segments based on $1.1B revenue
3.4 years to LOEPeak-stage brand with $1.1B annual spending signals established commercial infrastructure and stable team size, though high competitive pressure (8/10) indicates defensive positioning.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antibacterial
Indications (3)
Worked on XIFAXAN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.